Meridian Bioscience (VIVO) Misses Q4 EPS by 2c

Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.13, $0.02 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $49 million versus the consensus estimate of $48.05 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AeroVironment restates quarterly financials, citing $89M goodwill error
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target